相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III Study
Atul Deodhar et al.
ARTHRITIS & RHEUMATOLOGY (2021)
Comparison of short- and long-term effectiveness of ixekizumab and secukinumab in real-world practice
Giacomo Caldarola et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2021)
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
Kristian Reich et al.
LANCET (2021)
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
Kenneth B Gordon et al.
LANCET (2021)
Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab
A. B. Kimball et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis
Atul Deodhar et al.
JOURNAL OF RHEUMATOLOGY (2020)
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
Maxime Dougados et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
IκBζ is a key player in the antipsoriatic effects of secukinumab
Trine Bertelsen et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study
Andrea Chiricozzi et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2020)
Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5
Desiree van der Heijde et al.
RHEUMATOLOGY (2020)
Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
Z. Z. N. Yiu et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Real-world evidence of secukinumab in psoriasis treatment - a meta-analysis of 43 studies
M. Augustin et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
Inhibition of interleukins 17A and 17F in psoriatic arthritis
Peter Nash
LANCET (2020)
Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial
Christopher T Ritchlin et al.
LANCET (2020)
Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial
Atul Deodhar et al.
LANCET (2020)
Structural Analysis Reveals that the Cytokine IL-17F Forms a Homodimeric Complex with Receptor IL-17RC to Drive IL-17RA-Independent Signaling
Arnaud Goepfert et al.
IMMUNITY (2020)
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel -group, randomised, active-controlled, phase 3b trial
Iain B. McInnes et al.
LANCET (2020)
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
Laure Gossec et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F
Ralph Adams et al.
FRONTIERS IN IMMUNOLOGY (2020)
No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis
Therezia Bokor-Billmann et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2019)
Immunogenicity of Guselkumab Is Not Clinically Relevant in Patients with Moderate-to-Severe Plaque Psoriasis
Yaowei Zhu et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study
Tiago Torres et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study
Matteo Megna et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis
James G. Krueger et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years
K. Reich et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2019)
258 Secukinumab provides sustained improvements in the signs and symptoms in psoriatic arthritis: final 5-year efficacy and safety results from the FUTURE 1 Phase 3 trial
Hasan Tahir et al.
RHEUMATOLOGY (2019)
The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies
Dennis G. McGonagle et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Interleukin-17 receptor D constitutes an alternative receptor for interleukin-17A important in psoriasis-like skin inflammation
Yang Su et al.
SCIENCE IMMUNOLOGY (2019)
Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis
Gerard Bruin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis
Atul Deodhar et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation?
Stefan Siebert et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis
Stine Timmermann et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2019)
Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial
K. Reich et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study
Juergen Braun et al.
RHEUMATOLOGY (2019)
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
A. Deodhar et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study
Alan J. Kivitz et al.
RHEUMATOLOGY AND THERAPY (2019)
Interleukin-17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities
James G. Krueger et al.
EXPERIMENTAL DERMATOLOGY (2018)
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)
Desiree van der Heijde et al.
JOURNAL OF RHEUMATOLOGY (2018)
Mucocutaneous IL-17 immunity in mice and humans: host defense vs. excessive inflammation
J. Li et al.
MUCOSAL IMMUNOLOGY (2018)
Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis
Jillian Frieder et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2018)
Ixekizumab or secukinumab in psoriasis: what difference does it make?
C. Paul
BRITISH JOURNAL OF DERMATOLOGY (2018)
Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab
R. B. Warren et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Evaluation of the comorbidity burden in patients with ankylosing spondylitis using a large US administrative claims data set
Jessica A. Walsh et al.
CLINICAL RHEUMATOLOGY (2018)
Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies
Jorge R. Georgakopoulos et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5years of treatment (SCULPTURE Extension Study)
R. Bissonnette et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)
Psoriatic arthritis 1 The pathogenesis of psoriatic arthritis
Douglas J. Veale et al.
LANCET (2018)
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
Dominique Baeten et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
Andrew Blauvelt et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2018)
The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond
Nicolo Costantino Brembilla et al.
FRONTIERS IN IMMUNOLOGY (2018)
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological diseasemodifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
Desiree van der Heijde et al.
LANCET (2018)
Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab
Sebastian Spindeldreher et al.
DERMATOLOGY AND THERAPY (2018)
Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)
Peter Nash et al.
ARTHRITIS RESEARCH & THERAPY (2018)
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
β-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis
Frank Kolbinger et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis
Gerard Bruin et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial
Alice Gottlieb et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study
Jerry Bagel et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
Peter Nash et al.
LANCET (2017)
Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study
Iain B. McInnes et al.
RHEUMATOLOGY (2017)
Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence
Luisa Costa et al.
DRUGS IN R&D (2017)
The human IL-17A/F heterodimer: a two-faced cytokine with unique receptor recognition properties
Arnaud Goepfert et al.
SCIENTIFIC REPORTS (2017)
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
Desiree van der Heijde et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Secukinumab distributes into dermal interstitial fluid of psoriasis patients as demonstrated by open flow microperfusion
Christian Dragatin et al.
EXPERIMENTAL DERMATOLOGY (2016)
Psoriasis comorbidities: complications and benefits of immunobiological treatment
Andre Vicente Esteves de Carvalho et al.
ANAIS BRASILEIROS DE DERMATOLOGIA (2016)
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
K. B. Gordon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
Diamant Thaci et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)
Ulrich Mrowietz et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
Iain B. McInnes et al.
LANCET (2015)
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Dominique Baeten et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
Philip J. Mease et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Basic biology and role of interleukin-17 in immunity and inflammation
Camille Zenobia et al.
PERIODONTOLOGY 2000 (2015)
Comparative Genomic Profiling of Synovium Versus Skin Lesions in Psoriatic Arthritis
Jennifer Belasco et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Comprehensive Treatment of Psoriatic Arthritis: Managing Comorbidities and Extraarticular Manifestations
Alexis Ogdie et al.
JOURNAL OF RHEUMATOLOGY (2014)
Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials
Richard G. Langley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
IgG subclasses and allotypes: from structure to effector functions
Gestur Vidarsson et al.
FRONTIERS IN IMMUNOLOGY (2014)
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Bioavailability of IgG Administered by the Subcutaneous Route
Melvin Berger et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2013)
Crystal structures of interleukin 17A and its complex with IL-17 receptor A
Shenping Liu et al.
NATURE COMMUNICATIONS (2013)
Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis
J. Leman et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis
James G. Krueger et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)
Functional Specialization of Interleukin-17 Family Members
Yoichiro Iwakura et al.
IMMUNITY (2011)
The interleukin-17 cytokine family: critical players in host defence and inflammatory diseases
Rajita Pappu et al.
IMMUNOLOGY (2011)
Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis
Wolfgang Hueber et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection
M. Rudwaleit et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Structural basis of receptor sharing by interleukin 17 cytokines
Lauren K. Ely et al.
NATURE IMMUNOLOGY (2009)
New insights into the pathogenesis and genetics of psoriatic arthritis
Kristine E. Nograles et al.
NATURE CLINICAL PRACTICE RHEUMATOLOGY (2009)
Structure and signalling in the IL-17 receptor family
Sarah L. Gaffen
NATURE REVIEWS IMMUNOLOGY (2009)
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
W. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Regulation of inflammatory responses by IL-17F
Xuexian O. Yang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex
Jill F. Wright et al.
JOURNAL OF IMMUNOLOGY (2008)
Guidelines of care for the management of psoriasis and psoriatic arthritis - Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Etanercept treatment for children and adolescents with plaque psoriasis
Amy S. Paller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Psoriasis 1 - Pathogenesis and clinical features of psoriasis
Christopher E. M. Griffiths et al.
LANCET (2007)
Antibody pharmacokinetics and pharmacodynamics
ED Lobo et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients
EHS Choy et al.
RHEUMATOLOGY (2000)
分享论文
